UPR CHROME, Université de Nîmes, CEDEX 1, 30021, Nîmes, France.
J Cancer Res Clin Oncol. 2023 Aug;149(10):7981-7993. doi: 10.1007/s00432-023-04675-5. Epub 2023 Mar 14.
Gynecological cancers account for a large number of cancer-related deaths in women. Endometrial cancer is the most prevalent, while ovarian cancer is the deadliest gynecological cancer worldwide. To overcome the clinical need for easy and rapid testing, there is a growing interest in cancer detection in non-invasive modalities. With a growing field of liquid biopsy, urine became interesting source of cancer biomarkers.
The aim of this manuscript is to provide an overview on the origin, analysis and the clinical significance of urine microRNAs in gynecological cancers, with a focus on ovarian and endometrial cancer. MicroRNAs, a class of small non-coding nucleic acids, are emerging as a non-invasive biomarkers due to the feasibility and the extreme stability in body fluids. Specific miRNA expression signatures have been previously identified in ovarian and endometrial cancer.
The aim of this manuscript is to provide an overview on the origin, analysis and the clinical significance of urine microRNAs in gynecological cancers, with the focus on ovarian and endometrial cancer. CONCLUSION: The advantages and limitations of urine microRNA utility and technologies are discussed. Previously detected microRNA from urine of the patients are summarized to evaluate their potential as non-invasive clinical biomarkers in gynecological oncology.
妇科癌症导致了大量女性癌症相关死亡。子宫内膜癌是最常见的,而卵巢癌是全世界最致命的妇科癌症。为了满足临床对简便、快速检测的需求,人们对非侵入性检测方法中的癌症检测产生了浓厚的兴趣。随着液体活检领域的不断发展,尿液成为了癌症生物标志物的一个有趣来源。
本文旨在概述尿液 microRNAs 在妇科癌症(重点是卵巢癌和子宫内膜癌)中的起源、分析和临床意义。microRNAs 是一类小的非编码核酸,由于其在体液中的可行性和极高稳定性,作为非侵入性生物标志物而崭露头角。先前已经在卵巢癌和子宫内膜癌中鉴定出了特定的 miRNA 表达特征。
本文旨在概述尿液 microRNAs 在妇科癌症(重点是卵巢癌和子宫内膜癌)中的起源、分析和临床意义。
讨论了尿液 microRNA 应用和技术的优缺点。总结了从患者尿液中检测到的先前 microRNA,以评估它们作为妇科肿瘤学中无创临床生物标志物的潜力。